Amgen Total Current Liabilities from 2010 to 2024

AMGN Stock  USD 294.53  4.63  1.60%   
Amgen Total Current Liabilities yearly trend continues to be very stable with very little volatility. Total Current Liabilities is likely to grow to about 19.3 B this year. Total Current Liabilities is the total amount of liabilities that Amgen Inc is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
1986-03-31
Previous Quarter
21.5 B
Current Value
20.3 B
Quarterly Volatility
5.2 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Amgen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amgen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 B, Interest Expense of 3 B or Selling General Administrative of 5.8 B, as well as many indicators such as Price To Sales Ratio of 9.47, Dividend Yield of 0.0185 or PTB Ratio of 25.96. Amgen financial statements analysis is a perfect complement when working with Amgen Valuation or Volatility modules.
  
Check out the analysis of Amgen Correlation against competitors.

Latest Amgen's Total Current Liabilities Growth Pattern

Below is the plot of the Total Current Liabilities of Amgen Inc over the last few years. Total Current Liabilities is an item on Amgen balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Amgen Inc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Amgen's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amgen's overall financial position and show how it may be relating to other accounts over time.
Total Current Liabilities10 Years Trend
Slightly volatile
   Total Current Liabilities   
       Timeline  

Amgen Total Current Liabilities Regression Statistics

Arithmetic Mean10,750,553,333
Geometric Mean6,471,940,237
Coefficient Of Variation46.35
Mean Deviation3,833,356,444
Median11,204,000,000
Standard Deviation4,982,943,279
Sample Variance24829723.7T
Range19.3B
R-Value0.93
Mean Square Error3571638.3T
R-Squared0.87
Slope1,037,140,357
Total Sum of Squares347616132.1T

Amgen Total Current Liabilities History

202419.3 B
202318.4 B
202215.7 B
202112.2 B
202011.7 B
201912.8 B
201813.5 B

About Amgen Financial Statements

Amgen investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Amgen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Current Liabilities18.4 B19.3 B

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amgen Stock

  0.61A Agilent Technologies Earnings Call This WeekPairCorr
  0.78ME 23Andme HoldingPairCorr
  0.68VALN Valneva SE ADRPairCorr
  0.79JNJ Johnson Johnson Sell-off TrendPairCorr

Moving against Amgen Stock

  0.42MDGL Madrigal PharmaceuticalsPairCorr
  0.41KZR Kezar Life SciencesPairCorr
  0.33RNXT RenovoRxPairCorr
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.621
Dividend Share
8.88
Earnings Share
7.83
Revenue Per Share
60.641
Quarterly Revenue Growth
0.232
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.